stockportfolio.pro
Abrdn Life Sciences Investors (HQL)
Financial Services · Asset Management · NYSE
Abrdn Life Sciences Investors revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $-103.25M | $23.52M | $86.69M | $86.39M |
| Gross profit | — | — | — | — |
| Net income | $-104.60M | $22.35M | $85.30M | $85.59M |
| Net margin | 101.3% | 95.0% | 98.4% | 99.1% |
Source: Abrdn Life Sciences Investors SEC filings (10-K).
Explore 4 years of Abrdn Life Sciences Investors financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track HQL in your portfolio →
Abrdn Life Sciences Investors financial history by metric
About Abrdn Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Abrdn Life Sciences Investors — frequently asked questions
What is Abrdn Life Sciences Investors's revenue?
Abrdn Life Sciences Investors (HQL) reported revenue of $86.39M for fiscal year 2025, down 0.3% from the prior year, according to its SEC filings.
Is Abrdn Life Sciences Investors profitable?
Yes. HQL earned net income of $85.59M in fiscal 2025, a net margin of 99.1%.
What is HQL's P/E ratio?
Abrdn Life Sciences Investors trades at a price-to-earnings ratio of about 2.5 based on the latest data in our nightly-refreshed cache.
How much debt does Abrdn Life Sciences Investors have?
As of fiscal year 2025, HQL carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Abrdn Life Sciences Investors's market cap?
Abrdn Life Sciences Investors (HQL) has a market capitalization of about $508.74M, based on the latest data in our nightly-refreshed cache.
When does Abrdn Life Sciences Investors's fiscal year end?
HQL's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
Where does this data come from?
All figures are computed from Abrdn Life Sciences Investors's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.